Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 29th November 2018
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

NexGard range approved for treatment of serious skin diseases
Nexgard was the first oral medication to treat both fleas and ticks in dogs.
Label claims expanded for two brands in the EU and Australia

NexGard and NexGard Spectra have been approved for the treatment of two serious skin diseases in dogs, demodicosis and sarcoptic mange.

Boehringer Ingelheim received approval to expand the label claims for the brands, both in the EU and Australia.

Nexgard was the first oral medication to treat both fleas and ticks in dogs, while NexGard Spectra also protects against parasites such as heartworm, lungworm and the most common gastrointestinal parasites.

Canine demodicosis, or demodectic mange, is considered to be one of the most severe skin diseases in dogs and can be life threatening. It is caused by the Demodex canis mite, which lives in the hair follicles and sebaceous glands. The majority of dogs are healthy carriers and are able to inhibit mite proliferation.

If, however, a dog develops generalised demodicosis, it usually means the immune system is compromised.

Sarcoptic mange is a generalised dermatitis and is often hard to diagnose. It is caused by the highly contagious skin parasite, Sarcoptes scabiei. Mites burrow into the skin and cause severe itching, which may result in scabs and hair loss.

Professor Fred Beugnet, head of global veterinary technical services at Boehringer, said: “Sarcoptes mites are not only easily transferred between dogs, but are zoonotic parasites which can be passed from animals to humans. This is why the treatment of this disease is crucial for animals’ as well as humans’ health.”

Approval to expand the label claim was granted on the basis of three experimental studies and two well-controlled field studies. According to Boehringer, the canine demodicosis study showed an overall efficacy of more than 98 per cent, while the studies on sarcoptic mange showed at almost 100 per cent efficacy after just one administration. 

Become a member or log in to add this story to your CPD history

Strangles survey seeks views of horse owners

News Story 1
 With Strangles Awareness Week just around the corner (5-11 May), vets are being encouraged to share a survey about the disease with their horse-owning clients.

The survey, which has been designed by Dechra, aims to raise awareness of Strangles and promote best practices to prevent its transmission. It includes questions about horse owners' experiences of strangles, together with preventative measures and vaccination.

Respondents to the survey will be entered into a prize draw to win two VIP tickets to Your Horse Live 2025. To access the survey, click here 

Click here for more...
News Shorts
Vivienne Mackinnon elected BVA Scottish Branch President

The British Veterinary Association (BVA) has elected Vivienne Mackinnon as its new BVA Scottish Branch president.

Dr Mackinnon has over 30 years of experience in veterinary care, encompassing both small animal and mixed practice. She has worked in practices in Scotland, England, New Zealand and Australia, before joining APHA to work in frontline disease control.

In her speech, Dr Mackinnon reflected on the changes in Scotland's veterinary industry and highlighted her commitment to veterinary education.

Dr Mackinnon said: "I look forward to working with colleagues across the veterinary professions to improve animal health and welfare in the country and support veterinary workplaces."